camonsertib + niraparib

Camonsertib + niraparib is an investigational oral combination therapy for advanced solid tumors, particularly those harboring DNA damage response (DDR) pathway alterations. **Camonsertib** is a potent, selective small molecule inhibitor of ataxia telangiectasia and Rad3-related protein kinase (ATR), targeting tumor cells reliant on ATR signaling due to defective DNA repair mechanisms. **Niraparib** is an approved oral small molecule inhibitor of poly(ADP-ribose) polymerase-1/2 (PARP-1/2), which inhibits repair of single-strand DNA breaks, leading to synthetic lethality in cells with homologous recombination deficiency (e.g., BRCA1/2 mutations). This combination is designed to maximize anti-tumor efficacy by dual inhibition of complementary DNA repair pathways and potentially overcome resistance to PARP inhibitor monotherapy. It is under investigation predominantly in patients with relapsed or refractory ovarian, breast, pancreatic, prostate, and other solid tumors, including those with previous exposure to platinum chemotherapy and/or PARP inhibitors[1][2][3][5][7].

Other names

camonsertib plus niraparib